View Financial HealthGreen Star Products 配当と自社株買い配当金 基準チェック /06Green Star Products配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Mar 22Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 800,000,000 Price\Range: $0.0025 Discount Per Security: $0お知らせ • Mar 12Green Star Products, Inc. Appoints Miss Kristy as New PresidentGreen Star Products, Inc. announced it now has a new president. Miss Kristy Hunt has been appointed President of Green Star Products, Inc.お知らせ • Feb 27Green Star Products Announces Approving the Exclusive Licensing with Biotech ResearchMr. Joseph LaStella, President of Green Star Products, Inc. stated, “The Company has enough early votes to close the COVID-19 contract with BTR (Biotech Research, LLC).” The Company has already received 52% of shareholder’s votes, and over 90% have voted in favor of approving the exclusive licensing with Biotech Research. This approval ensures the final passage of the contract between Green Star Products and Biotech Research at the shareholders meeting. GSPI can now move ahead with this exclusive distribution agreement. For more details, please see press release dated December 21, 2020, titled: "Green Star Products: New Research Data Indicates 99.9% Effective Against The COVID-19 Virus.” The 2021 Special Shareholders Meeting is scheduled on March 3, 2021. Due to the COVID-19 pandemic, Green Star Products will not be holding an actual in-person stockholders meeting. In that web page can find a Letter to Stockholders with current information about Company operations, voting updates, and a Special Shareholder’s Discount Coupon Code for Viro Spectrum Shield (VSS) purchases and some information about this great anti-viral product. At the present time, Company is concentrating all its efforts on distribution of Viro Spectrum Shield, as it is of utmost importance that help save lives during this active pandemic. COVID-19 is mutating quickly and spreading throughout the world. VSS has been successfully tested against multiple viruses. It tested at 99.9% efficacy against the COVID-19 virus in vitro. Results verified by a United States Federally Accredited Laboratory prove that VSS is non-toxic and has shown Broad-Spectrum Antiviral capabilities. So many benefits to VSS, none more important than this formula can be used to combat the virus after infection as well as an all-natural preventative. Volunteers who were ill as a result of virus, many testing positive for the COVID-19 virus, used VSS and showed reversal of symptoms in 24-72 hours. See https://vssmt.net/for more information. VSS makes no claims, the evidence speaks for itself.お知らせ • Dec 20Green Star Products, Inc. Announces New Research Data Indicates 99.9% Effective Against the COVID-19 VirusGreen Star Products, Inc. announced it received new data from a US Federally Accredited Laboratory stating, "In three replications at 3% and 10% concentration [of normal dosage of Viro Spectrum Shield], 100% of the cells were protected from signs of infection by the SARS-CoV-2 [COVID-19] virus, in vitro". Additionally, Viro Spectrum Shield (VSS) was specifically tested and found to be effective against the COVID-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Furthermore, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for COVID-19, have experienced significantly improved health and reduction or elimination of symptoms usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization. Viro Spectrum Shield is a proprietary blend of natural herbs and native plants. Presently, the blend is considered a dietary supplement.お知らせ • Dec 13Green Star Products Signs Covid-19 Distribution ContractGreen Star Products, Inc. has signed a Distribution Contract with Biotech Research, LLC, to market/sell their Broad-Spectrum Antiviral Product, called Viro Spectrum Shield (VSS), in several South American countries. VSS has been tested by a US Federally Accredited Laboratory and has been successfully proven to inhibit SARS-CoV-2 (Covid-19) virus in vitro. VSS was specifically tested and found to be effective against the Covid-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Additionally, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for Covid-19, have experienced Significantly Improved Health and Reduction of Symptoms (or Elimination) usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization.決済の安定と成長配当データの取得安定した配当: GSPIの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: GSPIの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Green Star Products 配当利回り対市場GSPI 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (GSPI)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Chemicals)1.7%アナリスト予想 (GSPI) (最長3年)n/a注目すべき配当: GSPIは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: GSPIは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: GSPIの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: GSPIが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 21:18終値2026/05/22 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Green Star Products, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 22Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 800,000,000 Price\Range: $0.0025 Discount Per Security: $0
お知らせ • Mar 12Green Star Products, Inc. Appoints Miss Kristy as New PresidentGreen Star Products, Inc. announced it now has a new president. Miss Kristy Hunt has been appointed President of Green Star Products, Inc.
お知らせ • Feb 27Green Star Products Announces Approving the Exclusive Licensing with Biotech ResearchMr. Joseph LaStella, President of Green Star Products, Inc. stated, “The Company has enough early votes to close the COVID-19 contract with BTR (Biotech Research, LLC).” The Company has already received 52% of shareholder’s votes, and over 90% have voted in favor of approving the exclusive licensing with Biotech Research. This approval ensures the final passage of the contract between Green Star Products and Biotech Research at the shareholders meeting. GSPI can now move ahead with this exclusive distribution agreement. For more details, please see press release dated December 21, 2020, titled: "Green Star Products: New Research Data Indicates 99.9% Effective Against The COVID-19 Virus.” The 2021 Special Shareholders Meeting is scheduled on March 3, 2021. Due to the COVID-19 pandemic, Green Star Products will not be holding an actual in-person stockholders meeting. In that web page can find a Letter to Stockholders with current information about Company operations, voting updates, and a Special Shareholder’s Discount Coupon Code for Viro Spectrum Shield (VSS) purchases and some information about this great anti-viral product. At the present time, Company is concentrating all its efforts on distribution of Viro Spectrum Shield, as it is of utmost importance that help save lives during this active pandemic. COVID-19 is mutating quickly and spreading throughout the world. VSS has been successfully tested against multiple viruses. It tested at 99.9% efficacy against the COVID-19 virus in vitro. Results verified by a United States Federally Accredited Laboratory prove that VSS is non-toxic and has shown Broad-Spectrum Antiviral capabilities. So many benefits to VSS, none more important than this formula can be used to combat the virus after infection as well as an all-natural preventative. Volunteers who were ill as a result of virus, many testing positive for the COVID-19 virus, used VSS and showed reversal of symptoms in 24-72 hours. See https://vssmt.net/for more information. VSS makes no claims, the evidence speaks for itself.
お知らせ • Dec 20Green Star Products, Inc. Announces New Research Data Indicates 99.9% Effective Against the COVID-19 VirusGreen Star Products, Inc. announced it received new data from a US Federally Accredited Laboratory stating, "In three replications at 3% and 10% concentration [of normal dosage of Viro Spectrum Shield], 100% of the cells were protected from signs of infection by the SARS-CoV-2 [COVID-19] virus, in vitro". Additionally, Viro Spectrum Shield (VSS) was specifically tested and found to be effective against the COVID-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Furthermore, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for COVID-19, have experienced significantly improved health and reduction or elimination of symptoms usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization. Viro Spectrum Shield is a proprietary blend of natural herbs and native plants. Presently, the blend is considered a dietary supplement.
お知らせ • Dec 13Green Star Products Signs Covid-19 Distribution ContractGreen Star Products, Inc. has signed a Distribution Contract with Biotech Research, LLC, to market/sell their Broad-Spectrum Antiviral Product, called Viro Spectrum Shield (VSS), in several South American countries. VSS has been tested by a US Federally Accredited Laboratory and has been successfully proven to inhibit SARS-CoV-2 (Covid-19) virus in vitro. VSS was specifically tested and found to be effective against the Covid-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Additionally, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for Covid-19, have experienced Significantly Improved Health and Reduction of Symptoms (or Elimination) usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization.